Skip to main content
. 2026 Aug 24;14(9):1882. doi: 10.3390/biomedicines14091882
ACE Angiotensin-converting enzyme
ACEI Angiotensin-converting enzyme inhibitor
AngII Angiotensin II
ARBs Angiotensin II receptor blockers
CI Confidence interval
CTCAE Common Terminology Criteria for Adverse Events
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4
ECOG Eastern Cooperative Oncology Group
HR Hazard ratio
ICI Immune checkpoint inhibitor
ICIs Immune checkpoint inhibitors
IL-6 Interleukin-6
irAE Immune-related adverse event
irAEs Immune-related adverse events
MDSCs Myeloid-derived suppressor cells
NSCLC Non-small cell lung cancer
OS Overall survival
PD-1 Programmed cell death protein 1
PD-L1 Programmed death-ligand 1
PFS Progression-free survival
RAS Renin–angiotensin system
SCLC Small cell lung cancer
SPSS Statistical Package for the Social Sciences
TGF-β Transforming growth factor-beta
TME Tumor microenvironment
TNF-α Tumor necrosis factor-alpha